Targeting the HER-Kinase Axis in Cancer

Seminars in Oncology

Volumn 31, Issue 1 SUPPL. 3, 2004, Pages 9-20

  Gross, Mitchell E ^a   Shazer, Ronald L ^a   Agus, David B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTRAMUSTINE; GAMMA UROGASTRONE; GEFITINIB; GELDANAMYCIN; GENISTEIN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; LAPATINIB; MATUZUMAB; MDX 447; MDX H210; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HER2; PELITINIB; PERTUZUMAB; STAUROSPORINE; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ACNE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CARCINOGENESIS; CARDIOTOXICITY; CHILL; CLINICAL PATHWAY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; FEVER; FLUSHING; GENE OVEREXPRESSION; HUMAN; LUNG CANCER; MALIGNANT TRANSFORMATION; NAUSEA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 2142700147     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.01.005     Document Type: Article

References (105)

1. Downward J, Yarden Y, Mayes E, et al: Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307:521-527, 1984
2. Lin CR, Chen WS, Kruiger W, et al: Expression cloning of human EGF receptor complementary DNA: Gene amplification and three related messenger RNA products in A431 cells. Science 224:843-848, 1984
3. Boerner JL, Danielsen A, Maihle NJ: Ligand-independent oncogenic signaling by the epidermal growth factor receptor: V-ErbB as a paradigm. Exp Cell Res 284:111-121, 2003
4. Olayioye MA, Neve RM, Lane HA, et al: The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19:3159-3167, 2000
5. Prenzel N, Zwick E, Daub H, et al: EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402:884-888, 1999
6. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001
7. Carpenter G: ErbB-4: Mechanism of action and biology. Exp Cell Res 284:66-77, 2003
8. Jones JT, Akita RW, Sliwkowski MX: Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 447:227-231, 1999
9. Pinkas-Kramarski R, Soussan L, Waterman H, et al: Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467, 1996
10. Tzahar E, Pinkas-Kramarski R, Moyer JD, et al: Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J 16:4938-4950, 1997
11. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
12. Worthylake R, Opresko LK, Wiley HS: ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both erbB-2 and epidermal growth factor receptors. J Biol Chem 274:8865-8874, 1999
13. Muthuswamy SK, Gilman M, Brugge JS: Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 19: 6845-6857, 1999
14. Fendly B, Winget M, Hudziak R, et al: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50:1550-1558, 1990
15. Molina MA, Codony-Servat J, Albanell J, et al: Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 61:4744-4749, 2001
16. Albanell J, Codony J, Rovira A, et al: Mechanism of action of anti-HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4. Adv Exp Med Biol 532:253-268, 2003
17. Agus D, Akita R, Fox W, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002
18. Lara PN Jr, Meyers FJ, Gray CR, et al: HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer 94:2584-2589, 2002
19. Koeppen HK, Wright BD, Burt AD, et al: Overexpression of HER2/neu in solid tumours: An immunohistochemical survey. Histopathology 38:96-104, 2001
20. Zhau HE, Wan DS, Zhou J, et al: Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol Carcinog 5:320-327, 1992
21. Agus DB, Akita RW, Fox WD, et al: A potential role for activated HER-2 in prostate cancer. Semin Oncol 27:76-83; discussion 92-100, 2000
22. Nicholson RI, Hutcheson IR, Harper ME, et al: Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann N Y Acad Sci 963:104-115, 2002
23. Liang K, Ang KK, Milas L, et al: The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57:246-254, 2003
24. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
25. Sato JD, Kawamoto T, Le AD, et al: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1:511-529, 1983
26. Masui H, Kawamoto T, Sato JD, et al: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44:1002-1007, 1984
27. Divgi CR, Welt S, Kris M, et al: Phase I and imaging trial of indium 11-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 83:97-104, 1991
28. Goldstein NI, Prewett M, Zuklys K, et al: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311-1318, 1995
29. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914, 2000
30. Mendelsohn J, Fan Z: Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 89:341-343, 1997
31. Alper O, Bergmann-Leitner E, Bennett T, et al: Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 93:1375-1384, 2001
32. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/ neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
33. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
34. Schiller J, Langer CJ, Thor A, et al: Trastuzumab in combination with paclitaxel/carboplatin advanced non-small cell lung cancer: Final report of ECOG 2598. Proc Am Soc Clin Oncol 22:648, 2003 (abstr 2606)
35. Chee KG, Lara PN, Longmate J, et al: Trastuzumab (TRAS) and docetaxel (DOC) in HER2 (+) hormone refractory prostate cancer (HRPC): A California Cancer Consortium Screening and Phase II trial. Proc Am Soc Clin Oncol 22:403, 2003 (abstr 1620)
36. Hwang JJ, Sinicrope F, Safran H, et al: A phase II trial of irinotecan and trastuzumab (Herceptin) in patients (pts) overexpressing HER-2/neu in metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 20:142a, 2001 (abstr 565)
37. Keefe DL: Trastuzumab-associated cardiotoxicity. Cancer 95:1592-1600, 2002
38. Cappuzzo F, Gregorc V, Rossi E, et al: Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21:2658-2663, 2003
39. Pollack JR, Sorlie T, Perou CM, et al: Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 99:12963-12968, 2002
40. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
41. Agus DB, Gordon M, Taylor C, et al: Clinical activity in a phase I trial of HER-2-targeted rhuMAb 2C4 (pertuzumab) in patients with advanced solid malignancies (AST). Proc Am Soc Clin Oncol 22:192, 2003 (abstr 771)
42. Akiyama T, Ishida J, Nakagawa S, et al: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262:5592-5595, 1987
43. Bridges AJ: Chemical inhibitors of protein kinases. Chem Rev 101:2541-2572, 2001
44. Al-Obeidi FA, Lam KS: Development of inhibitors for protein tyrosine kinases. Oncogene 19:5690-5701, 2000
45. Ward WH, Cook PN, Slater AM, et al: Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 48:659-666, 1994
46. Ciardiello F, Caputo R, Bianco R, et al: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-1465, 2001
47. Smaill JB, Palmer BD, Rewcastle GW, et al: Tyrosine kinase inhibitors.15. 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido [d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem 42:1803-1815, 1999
48. Lichtner RB, Menrad A, Sommer A, et al: Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 61:5790-5795, 2001
49. Baselga J, Rischin D, Ranson M, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302, 2002
50. Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20:2240-2250, 2002
51. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
52. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 290:2149-2158, 2003
53. Giaccone G, Johnson D, Scagliotti GV, et al: Results of a multivariate analysis of prognostic factors of overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large phase III trials (INTACT 1 and 2). Proc Am Soc Clin Oncol 22:20, 2003 (abstr 2522)
54. Herbst RS: Erlotinib (Tarceva): An update on the clinical trial program. Semin Oncol 30:34-46, 2003
55. Rowinsky EK, Garrison M, Lorusso P, et al: Administration of CI-1033, an irreversible pan-erbB tyrosine kinase (TK) inhibitor is feasible on a 7-day-on/7-day-off schedule: A phase I, pharmacokinetic (PK), and food effect study. Proc Am Soc Clin Oncol 22:201, 2003 (abstr 807)
56. Rinehart JJ, Wilding G, Willson J, et al: A phase I clinical and pharmacokinetic (PK)/food effect study of oral CI-1033, a pan-erb B tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 22:205, 2003 (abstr 821)
57. Nemunaitis JJ, Eiseman I, Cunningham C, et al: A phase 1 trial of CI-1033, a pan-erbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 22:243, 2003 (abstr 974)
58. Mellinghoff IK, Tran C, Sawyers CL: Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI166 on human prostate cancer xenografts. Cancer Res 62:5254-5259, 2002
59. Brandt R, Wong AM, Hynes NE: Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents. Oncogene 20:5459-5465, 2001
60. Dumez H, Hoekstra R, Eskens F, et al: A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally 3 times a week to patients with advanced cancer. Proc Am Soc Clin Oncol 21:86a, 2002 (abstr 341)
61. Kaplan EH, Jones CM, Bergen MS: A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab refractory metastatic breast cancer. Proc Am Soc Clin Oncol 22:245, 2003 (abstr 981)
62. Belanger M, Jones CM, Germond C, et al: A phase II, open-label, multicenter study of GW572016 in patients with metastatic colorectal cancer refractory to 5-FU5-FU in combination with irinotecan and/or oxaliplatin. Proc Am Soc Clin Oncol 22:244, 2003 (abstr 978)
63. Morgan JA, Bukowski RM, Xiong H, et al: Preliminary report of a phase 1 study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), given in combination with gemcitabine to patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 22:197, 2003 (abstr 788)
64. Salazar R, Kohne CH, Tabernero J, et al: A phase 1/2A open-label study of EKB-569 in combination with CPT-11/5-FU/LV (FOLFIRI) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 22:222, 2003 (abstr 888)
65. Neckers L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8:S55-S61, 2002 (suppl)
66. Neckers L: Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: A novel therapeutic approach for treating hormone-refractory prostate cancer. Clin Cancer Res 8:962-926, 2002
67. Banerji U, O'Donnell A, Scurr M, et al: A pharmacokinetically (PK)-pharmacodynamically (PD) guided phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG). Proc Am Soc Clin Oncol 22:199, 2003 (abstr 797)
68. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
69. Scher HI, Sarkis A, Reuter V, et al: Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1:545-550, 1995
70. Maurizi M, Almadori G, Ferrandina G, et al: Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74:1253-1257, 1996
71. Turkeri L, Erton M, Cevik I, et al: Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology 51:645-649, 1998
72. Lipponen P, Eskelinen M: Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 69:1120-1125, 1994
73. Neal D, Sharples L, Smith K, et al: The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65:1619-1625, 1990
74. Mukaida H, Toi M, Hirai T, et al: Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer 68:142-148, 1991
75. Inada S, Koto T, Futami K, et al: Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today 29:493-503, 1999
76. Garcia I, Vizoso F, Martin A, et al: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10:234-241, 2003
77. Khalifa M, Abdoh A, Mannel R, et al: Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer 73:370-376, 1994
78. Reinartz JJ, George E, Lindgren BR, et al: Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 25:1075-1083, 1994
79. Scambia G, Benedetti-Panici P, Ferrandina G, et al: Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: Correlation with clinical outcome and response to chemotherapy. Br J Cancer 72:361-366, 1995
80. Skirnisdottir I, Sorbe B, Seidal T: The growth factor receptors HER-2/ neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer 11:119-129, 2001
81. Fischer-Colbrie J, Witt A, Heinzl H, et al: EGFR and steroid receptors in ovarian carcinoma: Comparison with prognostic parameters and outcome of patients. Anticancer Res 17:613-619, 1997
82. Kim Y, Park S, Kim J: Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol Oncol 87:84-89, 2002
83. Wong AJ, Ruppert JM, Bigner SH, et al: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89:2965-2969, 1992
84. Frederick L, Wang XY, Eley G, et al: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383-1387, 2000
85. Sadasivan R, Morgan R, Jennings S, et al: Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol 150:126-131, 1993
86. Mitra A, Murty V, Pratap M, et al: ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 54:637-639, 1994
87. Harpole DJ, Herndon JN, Wolfe W, et al: A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 55:51-56, 1995
88. Brabender J, Danenberg K, Metzger R, et al: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7:1850-1855, 2001
89. Kern J, Schwartz D, Nordberg J, et al: p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184-5187, 1990
90. Han H, Landreneau R, Santucci T, et al: Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol 33:105-110, 2002
91. Berchuck A, Kamel A, Whitaker R, et al: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50:4087-4091, 1990
92. Wong Y, Cheung T, Lam S, et al: Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer. Gynecol Obstet Invest 40:209-212, 1995
93. Hengstler J, Lange J, Kett A, et al: Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res 59:3206-3214, 1999
94. Saffari B, Jones L, el-Naggar A, et al: Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: Correlation with overall survival. Cancer Res 55:5693-5698, 1995
95. Hetzel D, Wilson T, Keeney G, et al: HER-2/neu expression: A major prognostic factor in endometrial cancer. Gynecol Oncol 47:179-185, 1992
96. Kapitanovic S, Radosevic S, Kapitanovic M, et al: The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112:1103-1113, 1997
97. Knosel T, Yu Y, Stein U, et al: Overexpression of c-erbB-2 protein correlates with chromosomal gain at the c-erbB-2 locus and patient survival in advanced colorectal carcinomas. Clin Exp Metastasis 19:401-407, 2002
98. Brien T, Depowski P, Sheehan C, et al: Prognostic factors in gastric cancer. Mod Pathol 11:870-877, 1998
99. Tabernero J, Rojo F, Jimenez E, et al: A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc Am Soc Clin Oncol 22:192, 2003 (abstr 770)
100. Kollmannsberger C, Schittenhelm M, Honecker F, et al: Epidermal growth factor receptor (EGFR) antibody EMD 72000 in combination with paclitaxel (P) in patients (pts) with EGFR-positive advanced non-small cell lung cancer (NSCLC): A phase-I study. Proc Am Soc Clin Oncol 22:627, 2003 (abstr 2520)
101. Meropol NJ, Berlin J, Hecht JR, et al: Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22:256, 2003 (abstr 1026)
102. Wang P, Fredlin P, Davis CG, et al: Therapeutic potential of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for the treatment of renal cell carcinoma. Proc Am Soc Clin Oncol 21:191a, 2002 (abstr 761)
103. Pfister D, Lipton A, Belt R, et al: A phase I trial of the epidermal growth factor receptor (EGFR)-directed bispecific antibody (BsAB) MDX-447 in patients with solid tumors. Proc Am Soc Clin Oncol 18:433a, 1999 (abstr 1667)
104. Winquist E, Nabid A, Sicheri D, et al: A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT). Proc Am Soc Clin Oncol 21:232a, 2002 (abstr 926)
105. Gadina M, Hilton D, Johnston JA, et al: Signaling by type I and II cytokine receptors: Ten years after. Curr Opin Immunol 13:363-373, 2001